1294 related articles for article (PubMed ID: 23953903)
1. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
2. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
4. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos AC; Turpie AG
Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
[TBL] [Abstract][Full Text] [Related]
6. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
[No Abstract] [Full Text] [Related]
7. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Quinlan DJ; Eriksson BI
Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
[TBL] [Abstract][Full Text] [Related]
9. New oral anticoagulants in the management of venous thromboembolism: a major advance?
Sciascia S; Hunt BJ
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
[No Abstract] [Full Text] [Related]
10. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Spanos K; Giannoukas AD
Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
[No Abstract] [Full Text] [Related]
11. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
[No Abstract] [Full Text] [Related]
12. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
Hurst KV; Lee R; Milosevic I; Handa A
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
[No Abstract] [Full Text] [Related]
13. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Dobesh PP; Fanikos J
Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
[TBL] [Abstract][Full Text] [Related]
14. Target-specific oral anticoagulants: practice issues for the clinician.
Plitt A; Giugliano RP
Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
16. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
19. [New anticoagulants in the prevention and treatment of venous thromboembolism].
Keltai M; Keltai K
Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
[TBL] [Abstract][Full Text] [Related]
20. Overview of the new oral anticoagulants: opportunities and challenges.
Yeh CH; Hogg K; Weitz JI
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]